PositiveID announces optics-enhanced Firefly DX prototype for pathogen detection

PositiveID Corp. introduced a new prototype of its Firefly Dx polymerase chain reaction (PCR) detection device, which detects pathogens, Monday.

“This new prototype system is a big step forward in the development of a commercially available Firefly Dx unit as we move to capture a portion of the multi-billion-dollar real-time PCR market,” William Caragol, chairman and CEO of PositiveID, told Bio Prep Watch. “By incorporating real-time optics into our system, we can begin to measure the presence of a pathogen in real-time, which is an integral component of the Firefly Dx value proposition.”

With added optic capabilities, the detection device is now able to determine the amount of pathogen or other contaminant in the area through the measurement of the sample’s fluorescence during the PCR process.

The company states that the Firefly Dx handheld detection device is capable of producing an accurate reading of a sample within a 20-minute time frame. This system would be able to help healthcare and emergency services personnel perform diagnostics in the field or in remote areas where current laboratory tests would be cumbersome or impossible.

This model prototype also eliminates the need for an external confirmation instrument for result confirmation.

Organizations in this Story


Want to get notified whenever we write about PositiveID ?
Next time we write about PositiveID, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.